热门标签

新2最新登录址:Sanofi ends cancer drug trials

时间:1个月前   阅读:7   评论:4

新2最新登录址www.zq18.vip)实时更新发布最新最快最有效的新2最新登录网址,包括新2最新登录手机网址,新2最新登录备用网址,皇冠新2最新登录网址,新2最新登录足球网址,新2最新登录网址大全。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠APPwww.hg108.vip)是一个开放皇冠即时比分、皇冠官网注册的平台。皇冠APP(www.hg108.vip)提供最新皇冠登录,皇冠APP下载包含新皇冠体育代理、会员APP。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:皇冠体育信用(www.hg108.vip)

下一篇:Telegram群发消息(www.tel8.vip):Analysts predict another election beating for Sarawak PKR

网友评论